Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 100 Published: April 29, 2022 Report Code: GMDGDHC22080TDB

The Tyrosine Protein Kinase Mer pipeline market research report provides a comprehensive overview on the therapeutics under development for Tyrosine Protein Kinase Mer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Tyrosine Protein Kinase Mer and features dormant and discontinued projects.

Key Therapy Areas in the Tyrosine Protein Kinase Mer Pipeline Drugs Market

In the MERTK pipeline drugs market the key therapy areas are Oncology, Central Nervous System, and Ophthalmology. Oncology has the highest number of pipeline products.

Tyrosine Protein Kinase Mer Drugs Market, by Therapy Areas

Tyrosine Protein Kinase Mer Drugs Market, by Therapy Areas

For more therapy area insights, download a free report sample

Key MoA in the Tyrosine Protein Kinase Mer Pipeline Drugs Market

Tyrosine Protein Kinase Mer Inhibitor has the highest number of pipeline products followed by Tyrosine Protein Kinase Mer Antagonist, and Tyrosine Protein Kinase Mer Activator.

Proto-Oncogene Tyrosine-Protein Kinase MER Pipeline Drugs Market, by MoA

Proto-Oncogene Tyrosine-Protein Kinase MER Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Tyrosine Protein Kinase Mer Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the MERTK pipeline drugs market are Oral, and Intraocular. Oral has the maximum number of pipeline products.

Tyrosine Protein Kinase Mer Pipeline Drugs Market Analysis, by RoA

Tyrosine Protein Kinase Mer Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Proto-Oncogene Tyrosine-Protein Kinase MER Pipeline Drugs Market

The key molecule types in the Tyrosine Protein Kinase Mer pipeline drugs market are Small Molecule, Monoclonal Antibody, and Gene Therapy.

Tyrosine Protein Kinase Mer Pipeline Drugs Market, by Molecule Type

Tyrosine Protein Kinase Mer Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Tyrosine Protein Kinase Mer Pipeline Drugs Market

The major companies in the MERTK pipeline drugs market are Mirati Therapeutics Inc, Meryx Inc, Celon Pharma SA, Eli Lilly and Co, Dong-A Socio Holdings Co Ltd, Exelixis Inc, F. Hoffmann-La Roche Ltd, Halia Therapeutics Inc, HEC Pharma Co Ltd, Hope Biosciences Inc, Incyte Corp, Inspirna Inc, Pfizer Inc, and Qurient Co Ltd.

Proto-Oncogene Tyrosine-Protein Kinase MER Pipeline Drugs Market, by Major Companies

Proto-Oncogene Tyrosine-Protein Kinase MER Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Tyrosine Protein Kinase Mer Pipeline Drugs Market Overview

Key Therapy Areas Oncology, Central Nervous System, and Ophthalmology
Key Mechanisms of action Tyrosine Protein Kinase Mer Inhibitor, Tyrosine Protein Kinase Mer Antagonist, and Tyrosine Protein Kinase Mer Activator
Key Routes of Administration Oral, and Intraocular
Key Molecule Types Small Molecule, Monoclonal Antibody, and Gene Therapy
Major Companies Mirati Therapeutics Inc, Meryx Inc, Celon Pharma SA, Eli Lilly and Co, Dong-A Socio Holdings Co Ltd, Exelixis Inc, F. Hoffmann-La Roche Ltd, Halia Therapeutics Inc, HEC Pharma Co Ltd, Hope Biosciences Inc, Incyte Corp, Inspirna Inc, Pfizer Inc, and Qurient Co Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tyrosine Protein Kinase Mer
  • The pipeline guide reviews pipeline therapeutics for Tyrosine Protein Kinase Mer by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tyrosine Protein Kinase Mer therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tyrosine Protein Kinase Mer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Tyrosine Protein Kinase Mer

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tyrosine Protein Kinase Mer
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

  • Antengene Corp Ltd

    Aucentra Therapeutics Pty Ltd

    Celldex Therapeutics Inc

    Celon Pharma SA

    Dong-A Socio Holdings Co Ltd

    Eli Lilly and Co

    Exelixis Inc

    F. Hoffmann-La Roche Ltd

    Halia Therapeutics Inc

    HEC Pharma Co Ltd

    Incyte Corp

    Inspirna Inc

    Mediolanum farmaceutici SpA

    Meryx Inc

    Mirati Therapeutics Inc

    Ono Pharmaceutical Co Ltd

    Pfizer Inc

    Qurient Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC

2.7.10.1) – Overview

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC

2.7.10.1) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC

2.7.10.1) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC

2.7.10.1) – Companies Involved in Therapeutics Development

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC

2.7.10.1) – Drug Profiles

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC

2.7.10.1) – Dormant Products

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC

2.7.10.1) – Discontinued Products

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC

2.7.10.1) – Product Development Milestones

Featured News & Press Releases

Dec 15, 2021: Exelixis announces initiation of phase 1b trial evaluating Xl092 in combination with immuno-oncology therapies in patients with advanced solid tumors

Sep 20, 2021: Mirati Therapeutics announces long-term survival results from an exploratory analysis of sitravatinib plus nivolumab in patients with non-squamous non-small cell lung cancer who are resistant to checkpoint inhibitors

Apr 11, 2021: BeiGene presents clinical data on Sitravatinib in combination with Tislelizumab at the AACR Annual Meeting 2021

Mar 18, 2021: Exelixis announces clinical trial collaboration and supply agreement with Merck and Pfizer to evaluate XL092 and Avelumab in various forms of locally advanced or metastatic urothelial carcinoma

Mar 10, 2021: BeiGene announces presentation of clinical data on Sitravatinib in combination with tislelizumab at the AACR Annual Meeting 2021

Jan 26, 2021: Qurient enrolls first patient in Q702 U.S. phase 1 study

Oct 26, 2020: Exelixis announces first patient enrolled in Phase 1 trial cohort evaluating XL092 in combination with Atezolizumab in patients with advanced solid tumors

Oct 09, 2020: Exelixis to present the preclinical profile and initial clinical pharmacokinetics of XL092, its next-generation oral tyrosine kinase inhibitor

Sep 18, 2020: Mirati Therapeutics presents phase 2 data on sitravatinib in combination with nivolumab in urothelial cancer At ESMO Virtual Congress

Jun 22, 2020: RGENIX presents results from preclinical safety and efficacy studies of RGX-019 at the 2020 AACR Annual Meeting

May 26, 2020: Qurient announces U.S. FDA clearance of IND application for Q702, a novel cancer immunotherapy

Feb 15, 2020: Mirati Therapeutics announces initial data in Renal Cell Carcinoma from ongoing investigator sponsored clinical trial Of Sitravatinib in combination With Nivolumab at The 2020 ASCO Genitourinary Cancers Syposium

Dec 13, 2019: Sitravatinib plus Tislelizumab show promise in platinum-resistant advanced ovarian cancer

Nov 09, 2019: Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting

Oct 23, 2019: Mirati Therapeutics announces presentation of interim phase 2 Sitravatinib data In Urothelial Carcinoma and Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Antengene Corp Ltd, 2022

Pipeline by Aucentra Therapeutics Pty Ltd, 2022

Pipeline by Celldex Therapeutics Inc, 2022

Pipeline by Celon Pharma SA, 2022

Pipeline by Dong-A Socio Holdings Co Ltd, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Exelixis Inc, 2022

Pipeline by F. Hoffmann-La Roche Ltd, 2022

Pipeline by Halia Therapeutics Inc, 2022

Pipeline by HEC Pharma Co Ltd, 2022

Pipeline by Incyte Corp, 2022

Pipeline by Inspirna Inc, 2022

Pipeline by Mediolanum farmaceutici SpA, 2022

Pipeline by Meryx Inc, 2022

Pipeline by Mirati Therapeutics Inc, 2022

Pipeline by Ono Pharmaceutical Co Ltd, 2022

Pipeline by Pfizer Inc, 2022

Pipeline by Qurient Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.